Conference abstract · 12 Sep 2016
Conference abstractPublished 13 Jun 2019
Expanded CD34+ cells for cardiac cell therapy
CellProthera, France
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: We previously demonstrated that intra-cardiac delivery of autologous peripheral blood-CD34+ stem cells, mobilized by granulocyte-colony stimulating factor (G CSF) and collected by leukapheresis after myocardial infarction, structurally and functionally repaired the damaged myocardial area. When used for cardiac indication, CD34+ cells are now considered as ATMP (Advanced Therapy Medicinal Product). We have industrialized their production by developing an automated device for ex-vivo CD34+ stem cell expansion, starting from a whole blood sample. Method: Blood samples were collected from healthy donors after G-CSF mobilization. Manufacturing procedures included: (1) isolation of total nuclear cells (2) CD34+ immunoselection (3) expansion and cell culture recovery in the device and (4) expanded CD34+cell immunoselection and formulation. The assessment of CD34+ cell counts, viability and immunophenotype and sterility tests were performed as quality tests. Result: We established graft acceptance criteria and performed validation processes in three cell therapy centers (CTCs). 59.4±36.8Ã?106 viable CD34+ cells were reproducibly generated as the final product from 220 mL whole blood containing 17.1±8.1x106 viable CD34+ cells. CD34+ identity, genetic stability and telomere length were consistent with those of basal CD34+ cells. Gram staining and mycoplasma and endotoxin analyses were negative in all cases. We confirmed the therapeutic efficacy of both CD34±cell categories in experimental AMI (Acute Myocardial Infarct) in immuno-deficient rats during pre-clinical studies. Discussion: This reproducible, automated, and standardized expansion process produces high numbers of CD34+ cells corresponding to the approved ATMP and paves the way for a phase I/IIb study in AMI, which is currently recruiting patients.
Subjects
EngineeringAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Opinion · 20 Feb 2025
CAR-T Cell Therapy: Expanding Applications beyond Hematologic Malignancies
Conference abstract · 2 Oct 2017
Comparative study between two ex vivo cell expansion models of CD34+ cells from cryopreserved umbilical cord blood co-cultured with encapsulated mesenchymal stem cells
Conference abstract · 27 Jul 2015
Preclinical and clinical results of a subset of CD34+ cells
Conference abstract · 2015
Cell-based therapy in patients with acute myocardial infarction and impaired left ventricular function could reduce major adverse cardiac events
More from this journal
The newest in Journal of Tissue Science and Engineering.
Brief report · 29 Dec 2025
Skin Tissue Engineering: Accelerating Wound Healing With Biomaterials
Opinion · 29 Dec 2025
Biomaterials, Cells, And Stimulation For Spinal Cord Repair
Brief report · 29 Dec 2025
Cardiac Tissue Engineering: Building a New Heart
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Tissue Science and Engineering
- SubjectEngineering
- BylineArticles whose byline prints “Claire Saucourt”

